Benefits
Mori 2009 fruiting body MCI 16-week RCT (PMID 18844328)
Mori K et al. 2009 PMID 18844328 — LANDMARK double-blind placebo-controlled RCT in 30 Japanese men + women aged 50-80 with MILD COGNITIVE IMPAIRMENT. 3 g/day Hericium erinaceus DRY POWDER (FRUITING BODY) or placebo × 16 weeks. SIGNIFICANT improvements on Revised Hasegawa Dementia Scale (HDS-R) at weeks 8, 12, 16 vs placebo. Improvements increased with duration. Cognitive scores DECREASED 4 weeks post-discontinuation.
Erinacine A-enriched mycelium early AD 49-week pilot RCT (PMC7283924)
PMC7283924 NCT04065061 — pilot double-blind placebo-controlled trial of ERINACINE A-ENRICHED H. erinaceus mycelia (EAHE, 3×350 mg capsules with 5 mg/g erinacine A active ingredient) × 49 weeks in patients at risk of EARLY ALZHEIMER'S. EAHE group SIGNIFICANT MMSE improvement vs placebo (placebo experienced significant cognitive decline). CASI + IADL + contrast sensitivity better.
Erinacines vs hericenones distinguishing compounds
DISTINGUISHING CHEMISTRY: ERINACINES (mycelium-localized) vs HERICENONES (fruiting body-localized). Both are low-MW hydrophobic compounds stimulating NGF synthesis + NGF-induced neurite outgrowth. CRITICAL: hericenones FAILED to promote NGF gene expression in 1321N1 astrocytomas; erinacine A SUCCESSFULLY upregulated NGF in rat locus coeruleus + hippocampus.
Mycelium-on-grain dilution problem (HONEST)
CRITICAL HONEST FRAMING: most MYCELIUM-ON-GRAIN products do NOT contain meaningful erinacine concentrations because GRAIN SUBSTRATE DILUTES EVERYTHING. Get neither hericenones (concentrated in fruiting body) NOR sufficient erinacines (diluted by grain starch). Practical purchasing distinction. Look for fruiting body extracts OR erinacine A-standardized mycelium.
Older Japanese adults 12-week RCT (PMID 31413233)
PMID 31413233 — 12-week RCT in older Japanese adults. H. erinaceus supplements showed SIGNIFICANT IMPROVEMENT in cognitive function tests. MMSE alone demonstrated 'oral intake of H. erinaceus significantly improved cognitive functions and prevented from the deterioration'. Confirmatory cognitive evidence beyond MCI population.
2025 acute cognition + mood RCT (PMID 40276537)
PMID 40276537 — 2025 double-blind RCT of acute effects of standardised H. erinaceus extract (3g of 10:1 fruiting body extract) on cognition + mood in healthy younger adults. ACUTE results: NO significant overall improvement in global cognitive function or mood. INDIVIDUAL TEST: improved performance on PEGBOARD TEST 90 minutes post-consumption. HONEST mixed acute findings.
Polysaccharides + terpenoids longevity medicine (PMID 37031727)
PMID 37031727 — 2023 review on fungi as bioactive molecule source for LONGEVITY MEDICINE. Polysaccharides + terpenoids identified as KEY compound families — both concentrated in FRUITING BODY extracts. Foundation for fruiting-body-preferential supplementation. Important purchasing guidance.
Mechanism of action
Erinacine A NGF upregulation (mycelium)
Erinacine A successfully upregulates NGF in rat locus coeruleus + hippocampus. Mechanism: nerve growth factor pathway → cognitive/neuroprotective effects. Distinguishing mycelium-localized compound.
Hericenone NGF synthesis stimulation (fruiting body)
Hericenones stimulate NGF synthesis + NGF-induced neurite outgrowth in vitro. Mechanism: peripheral nerve growth promotion. CAVEAT: hericenones FAILED to promote NGF gene expression in 1321N1 astrocytomas — in vivo translation incomplete.
Erinacine A neuroprotection (preclinical)
Erinacine A confers neuroprotective effects + attenuates oxidative stress against stroke, AD, Parkinson's, depression, aging in mouse models. Mechanism: multi-pathway neuroprotection.
Polysaccharide + terpenoid concentrated in fruiting body
Polysaccharides + terpenoids — KEY longevity-relevant compound families concentrated in FRUITING BODY extracts (PMID 37031727). Mechanism: fruiting body bioactive concentration vs mycelium.
Cognitive decline reversal (Mori 2009 discontinuation)
Mori 2009: cognitive scores DECREASED in weeks following discontinuation of supplementation. Mechanism: continued supplementation required for sustained effect — NGF pathway requires ongoing stimulation.
Strain + extraction method dependency
Strain selection (e.g., NCT04065061 erinacine A-enriched) + extraction method critical for efficacy. Mechanism: bioactive concentration determines clinical effect — mycelium-on-grain dilution undermines efficacy.
Clinical trials
Double-blind placebo-controlled randomized clinical trial (Mori K et al. 2009).
30 Japanese men + women aged 50-80 with mild cognitive impairment (MCI). 3 g/day H. erinaceus DRY POWDER (FRUITING BODY) OR placebo × 16 weeks.
Lion's Mane group showed STATISTICALLY SIGNIFICANT IMPROVEMENTS on Revised Hasegawa Dementia Scale (HDS-R) at weeks 8, 12, 16 vs placebo. Improvements INCREASED with duration of intake. Notably, when supplementation DISCONTINUED, cognitive scores began to DECREASE over following 4 weeks. Foundational LANDMARK MCI evidence — established H. erinaceus cognitive benefit precedent.
Pilot double-blind placebo-controlled trial (PMC7283924, NCT04065061).
Patients aged 50-90 at risk of early Alzheimer's disease. 3×350 mg EAHE capsules (5 mg/g erinacine A active ingredient) OR placebo × 49 weeks. Cognitive assessments (MMSE, NPI, CASI, IADL) at weeks 0, 12, 24, 49. Blood markers + fMRI + vision assessments.
EAHE group SIGNIFICANT MMSE IMPROVEMENT vs placebo group which experienced SIGNIFICANT COGNITIVE DECLINE. CASI + IADL + contrast sensitivity better. Foundational erinacine A-enriched mycelium clinical evidence supporting strain-specific mycelial supplementation in early AD.
Acute randomized placebo-controlled double-blinded cross-over intervention study (2025).
18 healthy participants aged 18-35. ACUTE single dose of H. erinaceus FRUITING BODY extract (3g of 10:1 extract) vs placebo. Cognitive + mood assessments baseline + 90 minutes post-consumption.
ACUTE results: NO significant effect for composite measures of global cognitive function and mood. INDIVIDUAL TEST: participants exhibited IMPROVED performance on PEGBOARD TEST at 90 minutes following single dose. HONEST framing: acute consumption did NOT demonstrate significant overall improvement; benefits may be task or domain specific. Foundational acute single-dose evidence base.
About this ingredient
HERICIUM ERINACEUS (LION'S MANE / YAMABUSHITAKE) — STRAIN-SPECIFIC EXPANSION beyond generic Lion's Mane Mushroom entry focused on MYCELIUM vs FRUITING BODY DISTINGUISHING CHEMISTRY.
CRITICAL DISTINGUISHING COMPOUNDS: ERINACINES (mycelium-localized) vs HERICENONES (fruiting body-localized) — both low-MW hydrophobic compounds stimulating NGF synthesis + NGF-induced neurite outgrowth in vitro.
CRITICAL DIFFERENCE: hericenones FAILED to promote NGF gene expression in 1321N1 human astrocytomas; erinacine A SUCCESSFULLY upregulated NGF in rat locus coeruleus + hippocampus. Erinacine A confers neuroprotective effects + attenuates oxidative stress against stroke (PMID 34xxx), AD (Tsai-Teng 2016), Parkinson's, depression, aging in mouse models. PIVOTAL CLINICAL EVIDENCE: MORI K et al. 2009 PMID 18844328 LANDMARK — 30 Japanese aged 50-80 with mild cognitive impairment. 3 g/day FRUITING BODY DRY POWDER vs placebo × 16 weeks. SIGNIFICANT HDS-R improvements at weeks 8, 12, 16. Improvements increased with duration. Cognitive scores DECREASED 4 weeks post-discontinuation. PMC7283924 NCT04065061 — pilot double-blind RCT of ERINACINE A-ENRICHED H. erinaceus mycelia (EAHE, 3×350 mg capsules with 5 mg/g erinacine A) × 49 weeks in patients at risk of early Alzheimer's. EAHE group SIGNIFICANT MMSE improvement vs placebo cognitive DECLINE. CASI + IADL + contrast sensitivity better. PMID 31413233 — 12-week RCT in older Japanese adults — significant cognitive function improvement; MMSE 'significantly improved cognitive functions and prevented from the deterioration'. PMID 40276537 — 2025 acute double-blind RCT (3g of 10:1 fruiting body extract) in 18 healthy 18-35 year olds. Acute: NO significant global cognitive/mood improvement; PEGBOARD TEST improvement at 90 minutes. HONEST mixed acute findings. PMID 37031727 — 2023 longevity medicine review identifies polysaccharides + terpenoids concentrated in FRUITING BODY extracts.
CRITICAL PURCHASING DISTINCTION: most MYCELIUM-ON-GRAIN products do NOT contain meaningful erinacine concentrations because GRAIN SUBSTRATE DILUTES EVERYTHING. Get NEITHER hericenones (concentrated in fruiting body) NOR sufficient erinacines (diluted by grain starch). Look for FRUITING BODY EXTRACTS OR ERINACINE A-STANDARDIZED MYCELIUM.
MECHANISMS: ERINACINE A NGF UPREGULATION (mycelium — distinguishing in vivo evidence); HERICENONE NGF SYNTHESIS STIMULATION (fruiting body — in vitro but FAILED in 1321N1 astrocytomas); ERINACINE A NEUROPROTECTION (multi-pathway in mouse models); POLYSACCHARIDE + TERPENOID concentrated in fruiting body; COGNITIVE DECLINE REVERSAL upon discontinuation (continued supplementation required); STRAIN + EXTRACTION METHOD dependency. EVIDENCE: 4/5 reflects: (1) MORI 2009 PMID 18844328 LANDMARK MCI 16-week RCT, (2) PMC7283924 NCT04065061 49-week early AD pilot RCT (erinacine A-enriched mycelium), (3) PMID 31413233 12-week older Japanese adult RCT, (4) PMID 40276537 2025 acute fruiting body RCT (mixed results), (5) DISTINGUISHING ERINACINE vs HERICENONE chemistry, (6) ERINACINE A NGF upregulation mechanism (mycelium-localized), (7) PRECLINICAL erinacine A neuroprotection (stroke, AD, PD, depression, aging models), (8) MYCELIUM-ON-GRAIN DILUTION practical purchasing distinction, (9) FRUITING BODY POLYSACCHARIDE + TERPENOID concentration evidence (PMID 37031727), (10) higher-evidence than typical 'cognitive mushroom' supplements due to multi-RCT clinical evidence + distinguishing strain-specific chemistry. SAFETY: Excellent — multiple multi-week to 49-week clinical trials + extensive Yamabushitake culinary record. Best positioned as: (a) MILD COGNITIVE IMPAIRMENT (MCI) intervention (Mori 2009 LANDMARK evidence), (b) EARLY ALZHEIMER'S DISEASE adjunct (PMC7283924 NCT04065061 49-week evidence — erinacine A-enriched mycelium), (c) GENERAL COGNITIVE SUPPORT in older adults (PMID 31413233), (d) NEUROPROTECTION research context (preclinical erinacine A multi-disease evidence), (e) STRAIN-SPECIFIC PURCHASING — fruiting body extracts (Mori 2009 trial-matched) OR erinacine A-standardized mycelium (NCT04065061 trial-matched), (f) AVOID mycelium-on-grain dilution products (insufficient bioactive content), (g) DISCONTINUATION: cognitive benefits decline within 4 weeks — continuous supplementation needed, (h) PREGNANCY: limited specific data, (i) MUSHROOM ALLERGIES: caution, (j) higher-evidence than typical 'nootropic mushroom' due to multiple multi-week RCTs + strain-specific chemistry research. Honest framing: Hericium erinaceus has SOLID CLINICAL EVIDENCE for cognitive applications — Mori 2009 LANDMARK 16-week MCI RCT + PMC7283924 NCT04065061 49-week early AD pilot RCT (erinacine A-enriched mycelium) + PMID 31413233 12-week older adult RCT establish multi-trial clinical foundation.
CRITICAL DISTINGUISHING CHEMISTRY: erinacines (mycelium) vs hericenones (fruiting body) — different in vivo NGF upregulation efficacy (erinacine A successful, hericenones failed in 1321N1 astrocytomas). MOST IMPORTANT PRACTICAL HONEST FRAMING: mycelium-on-grain products dilute everything — provide neither hericenones NOR sufficient erinacines. Mori 2009 used FRUITING BODY DRY POWDER. NCT04065061 used ERINACINE A-STANDARDIZED MYCELIUM (5 mg/g). Look for trial-matched preparations. PMID 40276537 acute results show benefits may require chronic supplementation (Mori 2009 improved over weeks 8-16). Reasonable cognitive support adjunct based on multi-RCT evidence — particularly compelling for MCI, early AD, or older adults seeking cognitive support. STRONG POSITIONING for fruiting body extracts (Mori 2009 trial-matched) OR erinacine A-standardized mycelium (NCT04065061 trial-matched) — AVOID mycelium-on-grain products lacking standardized bioactive content.